Onkológia 3/2017

New trends in the treatment of Ph+ acute lymphoblastic leukemia

Aim: Philadelphia chromosome (Ph) – positive acute lymphoblastic leukemia (Ph+ ALL) represents about 20-30% of ALL in adulthood. It has very unfavorable prognosis. The use of standard combination chemotherapy (CHT) usually does not yield satisfactory results (remission duration and survival is short). Efficacy of Ph+ All treatment has reached a positive efect after the introduction target therapy. Tyrosine kinase inhibitors (TKIs) administered with standard chemotherapy in Ph+ ALL patients improved the outcome of these high-risk patients. Case: In our work, we describe a case of a 24-year-old male patient with relapsed / refractory B-ALL (Ph+) who, in addition to standard CHT, was treated with target therapy (ponatinib and blinatumomab). Conclusion: The combination of TKI with CHT increases the overall remission (CR) and overall survival (OS) in patients with Ph+ ALL.

Keywords: Ph+ acute lymphoblastic leukemia, BCR/ABL gene, chemotherapy, tyrosine kinase inhibitors, overall survival